U.S. markets closed
  • S&P 500

    4,185.47
    +15.05 (+0.36%)
     
  • Dow 30

    34,200.67
    +164.68 (+0.48%)
     
  • Nasdaq

    14,052.34
    +13.58 (+0.10%)
     
  • Russell 2000

    2,262.67
    +5.60 (+0.25%)
     
  • Crude Oil

    63.07
    -0.39 (-0.61%)
     
  • Gold

    1,777.30
    +10.50 (+0.59%)
     
  • Silver

    26.04
    +0.08 (+0.29%)
     
  • EUR/USD

    1.1980
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • GBP/USD

    1.3840
    +0.0056 (+0.41%)
     
  • USD/JPY

    108.7900
    +0.0740 (+0.07%)
     
  • BTC-USD

    60,491.52
    -1,026.22 (-1.67%)
     
  • CMC Crypto 200

    1,398.97
    +7.26 (+0.52%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,683.37
    +40.68 (+0.14%)
     

Ionis Antisense Oligonucleotides To Be Evaluated With Progenity's Drug Delivery System

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Progenity Inc (NASDAQ: PROG) has announced an agreement with Ionis Pharmaceuticals Inc (NASDAQ: IONS) to evaluate the safety, tolerability, and performance of Progenity's Oral Biotherapeutics Delivery System (OBDS) for oral-systemic delivery of Ionis developed antisense oligonucleotides.

  • The OBDS is an ingestible capsule based on a needle-free technology to enable the delivery of a drug formulated in a solution directly into the tissues of the small intestine, where it can be absorbed systemically.

  • During the first phase of the study, Progenity and Ionis will evaluate the OBDS in conjunction with Ionis' drug for in vitro compatibility and performance and in vivo safety, tolerability, and performance in a preclinical canine model.

  • Price Action: PROG shares are up 0.3% at $4.95, while IONS stock is up 1.12% at $47.37 on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.